Biol. Pharm. Bull. 29(9) 1886—1891 (2006)

نویسندگان

  • Sadahiko SHIMOEDA
  • Shin OHTA
  • Hikaru KOBAYASHI
  • Susumu YAMATO
  • Mutsuko SASAKI
چکیده

tion mechanism from existing antifungal agents, and its clinical efficacy is expected. MCFG exhibits a wide antifungal spectrum against Candida and Apergillus species in vitro by inhibiting biosynthesis of the major fungal cell wall component, 1,3-b-D-glucan. Its superior transfer to the lung may be highly effective for prevention and treatment of pulmonary mycosis. Clinically, MCFG is particularly important for treatment of pulmonary aspergillosis, which is problematic in patients with blood diseases. We previously reported that a 150 mg or higher daily dose is necessary for treatment of pulmonary aspergillosis with MCFG alone for patients with blood diseases from our clinical experience. However, we often encounter cases in which no therapeutic effect is obtained despite MCFG being administered at a sufficient dose, and a dose increase of MCFG or switch to other drugs is necessary. Moreover, no clear basis for dose adjustment is available for MCFG dose reduction in patients with severe impairment of renal or liver function. If the blood MCFG level does not reach the therapeutic level and delays treatment of pulmonary aspergillosis, it may have a major influence on patient survival. Clarification of the effective blood concentration of MCFG by evaluating its clinical effect enables rapid and accurate treatment. Establishment of an appropriate dose is also useful for reducing the risk of adverse effects, such as MCFG-induced impairment of liver function. Aiming for the rapid and safe treatment of pulmonary aspergillosis, we established new clinical diagnostic criteria of mycosis and a clinical improvement rating associated with MCFG administration, and investigated the effective blood concentration of MCFG for mycosis. The effective blood trough level of MCFG for pulmonary aspergillosis, which has not previously been established, was determined. The findings promoted rapid and safe treatment of pulmonary aspergillosis in patients with blood diseases. MATERIALS AND METHODS

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Antiinflammatory Constituents of Teramnus labialis

1. Alagarsamy, V., Raja Salomon, V., Vanikavitha, G., Paluchamy, V., Ravichandran, M., Arnold Sujin, A., Thangathirupathy, A., Amuthalakshmi, S. and Revathi R., Biol. Pharm. Bull., 2002, 25, 1432. 2. Alagarsamy, V., Muthukumar, V., Pavalarani, N., Vasanthanathan, P. and Revathi R., Biol. Pharm. Bull., 2003, 26(4), 557. 3. Chaurasia, M.R. and Sharma, S.K., Arch. Pharm., 1982, 315, 377. 4. Manabu...

متن کامل

Biol. Pharm. Bull. 29(3) 503—507 (2006)

can be sources of infection. However, since nebulization solutions are classified as external preparations, their hygienic management tends to be neglected at present. We investigated the microbial contamination of nebulization solutions in use from ultrasonic nebulizers commonly used in nebulizer therapy. In addition, the methods of preventing the microbial contamination of these nebulization ...

متن کامل

Biol. Pharm. Bull. 29(2) 191—201 (2006)

38997.htm; Accessed on 27/07/2005. 76) Puripattanavong J., Weber S., Brecht V., Frahm A. W., Planta Med., 66, 740—745 (2000). 77) Mulholland D. A., Randrianarivelojosia M., Lavaud C., Nuzillard J. M., Schwikkard S. L., Phytochemistry, 53, 115—118 (2000). 78) Hallur G., Sivaramakrishnan A., Bhat S. V., J. Nat. Prod., 65,

متن کامل

Biol. Pharm. Bull. 29(10) 2051—2055 (2006)

aceae), is one of the most widely prescribed and intensively studied herbal medicines. Ginsenosides, the secondary metabolites and unique constituents in the Panax plants, are the pharmacologically active ingredients of ginseng. There are two traditional preparations of ginseng, white ginseng (WG) and red ginseng (RG), the dried root of ginseng and the steamed/dried root of ginseng, respectivel...

متن کامل

Increases Lipoprotein Lipase Activity with Resulting Elevation of High Density Lipoprotein Cholesterol, and Long-term Administra tion Inhibits Atherogenesis in the Coronary Arteries of Rats

Kazuhiko Tsutsumi, et al., “The Novel Compound NO-1886 Increases Lipoprotein Lipase Activity with Resulting Elevation of High Density Lipoprotein Cholesterol, and Long-term Administra tion Inhibits Atherogenesis in the Coronary Arteries of Rats with Experimental Atherosclerosis”. J. Clin. Invest., vol. 92, pp. 411-417 (Jul 1993). Kazuhiko Tsutsumi, et al., “Suppression of Hyperlipidemia-Associ ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006